However, as exemplified by BCR-ABL1 in chronic myeloid leukemia and ALK fusions in lung carcinomas and mesenchymal tumors, gene fusions may play critical roles in tumorigenesis and present as attractive targets for therapeutic intervention (18, 66, 67). This evidence concerns the gene ALK and mesenchymal cell neoplasm.